Jade Biosciences, Inc.

JBIONASDAQHealthcareBiotechnology

$14.50- (-)1Y +50.15%

As of Oct 26, 2026 close

Market cap: $885.42M
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $8.36$28.00
Volume (live): -
Avg. volume (3M): 985.21K

Jade Biosciences, Inc. (JBIO) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Jade Biosciences, Inc. stock.

Analyst Consensus Rating

Investment consensus from 10 professional research analysts

Consensus Rating

Buy

Based on 10 unique analysts

(14 total ratings in last 90 days)

High Confidence∞:1 Buy/Sell

Average Price Target

$50.50

+248.28% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest JBIO Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 16, 2026	Vamil Divan	Guggenheim	Reiterates	Buy	$47.00
Oct 1, 2026	David Nierengarten	Wedbush	Maintains	Buy	$47.00
Oct 1, 2026	Vamil Divan	Guggenheim	Reiterates	Buy	$47.00
Oct 1, 2026	Arthur He CFA	HC Wainwright	Maintains	Buy	$55.00
Sep 30, 2026	Rami Katkhuda	LifeSci Capital	Maintains	Buy	$42.00
Sep 30, 2026	Matt Phipps	William Blair	Reiterates	Buy	-
Sep 4, 2026	Kaveri Pohlman	Clear Street	Initiates Coverage	Buy	$25.00 → $48.00 +23.00 (+92.0%)
Sep 3, 2026	Kaveri Pohlman	Clear Street	Reiterates	Buy	$25.00 → $48.00 +23.00 (+92.0%)
Aug 13, 2026	Alex Thompson CFA	Stifel Nicolaus	Maintains	Buy	$40.00
Aug 11, 2026	Akash Tewari	Jefferies	Maintains	Buy	$40.00 → $48.00 +8.00 (+20.0%)
Aug 10, 2026	Vamil Divan	Guggenheim	Reiterates	Buy	$47.00
Aug 10, 2026	Matt Phipps	William Blair	Maintains	Buy	-
Aug 10, 2026	Julian Harrison	BTIG	Maintains	Buy	$74.00 → $77.00 +3.00 (+4.0%)
Aug 10, 2026	Tyler Van Buren	TD Cowen	Maintains	Buy	-

Vamil Divan

Guggenheim

BuyReiterates

$47.00

Oct 16

David Nierengarten

Wedbush

BuyMaintains

$47.00

Oct 1

Vamil Divan

Guggenheim

BuyReiterates

$47.00

Oct 1

Arthur He CFA

HC Wainwright

BuyMaintains

$55.00

Oct 1

Rami Katkhuda

LifeSci Capital

BuyMaintains

$42.00

Sep 30

Matt Phipps

William Blair

BuyReiterates

Sep 30

Kaveri Pohlman

Clear Street

BuyInitiates Coverage

$25.00 → $48.00

Sep 4

Kaveri Pohlman

Clear Street

BuyReiterates

$25.00 → $48.00

Sep 3

Alex Thompson CFA

Stifel Nicolaus

BuyMaintains

$40.00

Aug 13

Akash Tewari

Jefferies

BuyMaintains

$40.00 → $48.00

Aug 11

Vamil Divan

Guggenheim

BuyReiterates

$47.00

Aug 10

Matt Phipps

William Blair

BuyMaintains

Aug 10

Julian Harrison

BTIG

BuyMaintains

$74.00 → $77.00

Aug 10

Tyler Van Buren

TD Cowen

BuyMaintains

Aug 10

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 16, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for JBIO?

The analyst consensus rating for JBIO is Buy, based on the latest ratings from 10 analysts over the last 90 days.

What is the average price target for JBIO?

The average 12-month price target for JBIO is $50.50, representing an upside of 248.3% from the Oct 26, 2026 close of $14.50.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.